RESUMO
Obesity is a challenging chronic disease process that continues to affect a large percentage of the population at large. With the advent of new therapeutic options and interventions and a deeper scientific understanding of obesity as a complex illness, there is hope in curtailing this evolving pandemic. In this article, we present key medical information to engage and empower nutrition-focused providers to manage obesity and its nutrition complications. The topics summarized here were presented during the 2023 American Society for Parenteral and Enteral Nutrition Preconference Physician Course and include pathophysiology and hormonal regulation of obesity, multidisciplinary care planning and nutrition risk stratification of patients, and common approaches to treatment, including lifestyle modifications, antiobesity medications, and procedures from the perspective of the nutrition specialist.
Assuntos
Obesidade , Humanos , Obesidade/terapia , Fármacos Antiobesidade/uso terapêutico , Médicos , Nutrição Parenteral/métodos , Estilo de Vida , Nutrição Enteral/métodos , NutricionistasAssuntos
Síndrome Torácica Aguda/prevenção & controle , Anemia Falciforme/terapia , Síndrome Torácica Aguda/diagnóstico , Síndrome Torácica Aguda/epidemiologia , Síndrome Torácica Aguda/etiologia , Adulto , Plantão Médico , Assistência Ambulatorial , Anemia Falciforme/complicações , Terapia Combinada , Redução de Custos , Erros de Diagnóstico , Gerenciamento Clínico , Transfusão de Eritrócitos , Transfusão Total , Feminino , Hospitalização/economia , Humanos , Incidência , Tempo de Internação/economia , Tempo de Internação/estatística & dados numéricos , Masculino , Equipe de Assistência ao Paciente , Estudos Retrospectivos , Centros de Atenção Terciária , Resultado do TratamentoRESUMO
INTRODUCTION: Bariatric surgery is effective therapy for weight loss and diabetes control. While patients with poorly controlled type 2 diabetes (T2D) experience significant benefit from bariatric surgery, the impact of hyperglycemia on perioperative risks is unclear. OBJECTIVE: This study aims to investigate effect of elevated glycated hemoglobin (HbA1C) on perioperative risks for patients undergoing sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB). SETTINGS: 117,644 patients undergoing RYGB or SG between the years of 2017 and 2018 in the United Stated were analyzed. Data was obtained using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database. METHODS: Three commonly used cutoff levels of HbA1C were selected (6.5, 7.0, and 8.5). Complications were compared between groups of patients above and below each HbA1C level. Multivariable logistic regression models were used to account for confounders. RESULTS: Without risk adjustment, HbA1C is indirectly associated with increased rates of surgical complications. However, after adjusting for underlying co-morbidities, HbA1C is not associated with overall complications, including 30 day readmissions, reoperations, reinterventions, or death at any HbA1C cutoff: 6.5 (odds ratio [OR] 1.041, P value = .219), 7.0 (OR 1.020, P value = .551), or 8.5 (OR 1.051, P value = .208). CONCLUSION: There is no direct relationship between HbA1C and early postoperative complications of SG and RYGB. Thus, optimizing preoperative HbA1C values alone, may not translate into decreased surgical complications of bariatric surgery. (Surg Obes Relat Dis 2020;17:271-275.) © 2020 American Society for Metabolic and Bariatric Surgery. All rights reserved.